Patent application number | Description | Published |
20090010961 | Avirulent, immunogenic flavivirus chimeras - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second | 01-08-2009 |
20100137571 | DENGUE SEROTYPE 1 ATTENUATED STRAIN - The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain. | 06-03-2010 |
20100174057 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 07-08-2010 |
20100255030 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 10-07-2010 |
20110150771 | CHIMERIC WEST NILE/DENGUE VIRUSES - The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins. | 06-23-2011 |
20120014981 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 01-19-2012 |
20120083584 | DENGUE SEROTYPE 1 ATTENUATED STRAIN - The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain. | 04-05-2012 |
20120083585 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 04-05-2012 |
20140141040 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 05-22-2014 |
20150031857 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 01-29-2015 |
Patent application number | Description | Published |
20100067114 | Direct Beam Solar Light System - A direct beam solar lighting system for collecting and distributing sunlight into a room. The system includes a rotatable solar collector head to receive sunlight and to reflect the sunlight downward into a transition tube having a reflective interior surface. The light-concentrating transition tube reflects sunlight into a reflective light tube which directs the reflected sunlight through a plenum space into the room. The system includes a drive mechanism for rotating the rotatable solar collector, and a light fixture at end of the light tube to disburse said reflected sunlight onto a ceiling and a wall in the room. In an embodiment the system includes one or more homogenizing reflectors within the solar collector for collecting the sunlight and directing the sunlight more uniformly over the aperture of the transition tube. In an alternative embodiment, the solar collector includes a rotatable tiltable mirror for providing two-axis tracking. | 03-18-2010 |
20100332034 | System and Method for an Electrical Insulating Shutter System - A system, and a method for manufacturing that system, for electrically and automatically opening, closing and otherwise controlling window shutters on a building, for the purposes of limiting radiant, conductive, and convective thermal losses from the inside of the building to the outside during the heating season, and limiting radiant, conductive, and convective thermal gains from the outside of the building to the inside during the cooling season. The system further comprises an interface to accommodate connection to other sensors not used to control the thermal environment of the building, such as motion detectors, burglar alarms, CO sensors and the like. | 12-30-2010 |
Patent application number | Description | Published |
20100137571 | DENGUE SEROTYPE 1 ATTENUATED STRAIN - The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain. | 06-03-2010 |
20100144015 | COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH - Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size. | 06-10-2010 |
20100174057 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 07-08-2010 |
20120083584 | DENGUE SEROTYPE 1 ATTENUATED STRAIN - The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain. | 04-05-2012 |
20120083585 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 04-05-2012 |
20150031857 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 01-29-2015 |
Patent application number | Description | Published |
20090010961 | Avirulent, immunogenic flavivirus chimeras - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second | 01-08-2009 |
20100255030 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 10-07-2010 |
20110150771 | CHIMERIC WEST NILE/DENGUE VIRUSES - The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins. | 06-23-2011 |
20120014981 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 01-19-2012 |
20140141040 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 05-22-2014 |
20140302088 | COMPOSITIONS AND METHODS FOR DENGUE VIRUS CHIMERIC CONSTRUCTS IN VACCINES - Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells. | 10-09-2014 |